N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.

Int J Mol Sci · 2026 · PMC13074174 · PMID 41977262

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.3100

boldest claim

The sentences

approaching significancep = 0.052so close (0.05 < p ≤ 0.1)

The mean number of headache episodes per month decreased by 3.0 ± 3.5 in the NEC group ( p = 0.004) compared to 1.4 ± 2.7 in the sham group ( p = 0.073), with the between-group difference approaching significance ( p = 0.052).

also in 2,640 other papers

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

A subgroup analysis by onset type showed a trend toward a benefit in patients with limb onset (74% vs. 51%, HR 0.5, p = 0.06), while patients with bulbar onset showed no benefit (44% vs. 62%, HR 1.66, p = 0.36).

also in 53,322 other papers

did not reach statistical significancep = 0.31not close (p > 0.1)

Regarding the primary outcome of survival, at the end of the 12-month study period, survival was higher in the NAC group (35/54, 65%) compared to placebo (30/56, 54%), but the difference did not reach statistical significance ( p = 0.31; hazard ratio 0.74, 95% CI: 0.41–1.33).

also in 111,027 other papers

a decreasing trendno p-value reported

[ 24 ] reported that the erythrocyte GSSG/GSH ratio had a decreasing trend in the NAC group, although it was not statistically significant (0.082 → 0.065 → 0.061 at 0, 16, 36 weeks; p = 0.09).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.